Maurizio Fava, MD

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

  • 145Articles
  • 733.4KReads
  • 1998–2025Active
  • 434Collaborators
  • 3KCitations

About

Maurizio Fava, MD, is affiliated with the Department of Psychiatry at Massachusetts General Hospital in Boston. With a publication record spanning from 1998 to 2025, Dr. Fava has authored 145 articles focusing on major depressive disorder, treatment-resistant depression, and related psychiatric conditions. His research covers clinical trials and analyses involving antidepressant therapies, including esmethadone, cariprazine, and intranasal esketamine, as well as complementary treatments such as yoga. Dr. Fava's work also addresses topics in suicide, sexual dysfunction, schizophrenia, neurology, and weight management within psychiatric practice.

Publications

JCP
Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis
Original Research

Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Antidepressant Tachyphylaxis

October 6, 2025

Esmethadone may be a potentially safe and effective adjunctive treatment for patients with MDD and antidepressant tachyphylaxis.
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Adjunctive Cariprazine for Anxiety Symptoms in MDD
Original Research

Adjunctive Cariprazine for Anxiety Symptoms in MDD

April 30, 2025

Cariprazine added to antidepressant therapy reduced anxiety symptoms in patients with and without anxiety at baseline.
, , , et al
JCP
Long-Term Safety and Efficacy of Esmethadone in MDD
Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

February 17, 2025

A durable improvement in MDD symptoms for up to 1 year was observed with esmethadone with high rates of response and remission.
, , , et al
JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Effect of Time From Onset of MDD on Response to Esmethadone
Original Research

Effect of Time From Onset of MDD on Response to Esmethadone

May 13, 2024

Esmethadone 25 and 50 mg were more effective in reducing depression scale scores in patients who had a shorter time since their first major depressive episode.
, , , et al
JCP
Heated Yoga for Depression
Original Research

Heated Yoga for Depression

October 23, 2023

Approximately 1 heated yoga session per week for 8 weeks led to significantly greater reduction in depression symptoms than a waitlist control.
, , , et al
JCP
Adjunctive Cariprazine for MDD With Inadequate Response to Antidepressants
Original Research

Adjunctive Cariprazine for MDD With Inadequate Response to Antidepressants

August 16, 2023

This study assessed the efficacy of adjunctive use of cariprazine, an atypical antipsychotic, in MDD patients with inadequate response to antidepressants.
, , , et al
JCP
In Memoriam: Joseph Biederman, MD
In Memoriam

In Memoriam: Joseph Biederman, MD

February 22, 2023

Colleagues and friends remember Joseph Biederman and reflect on his legacy as the father of pediatric psychopharmacology.
, , , et al
PCC
REL-1017 Effects on Cognition in MDD
Original Research

REL-1017 Effects on Cognition in MDD

February 14, 2023

REL-1017 improved subjective measures of cognitive impairment, in addition to improving total MADRS and SDQ scores.
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
Original Research

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe